September S&P 500 E-Mini futures (ESU25) are up +0.87%, and September Nasdaq 100 E-Mini futures (NQU25) are up +1.15% this morning as sentiment got a boost after U.S. President Donald Trump announced a ceasefire between Israel and Iran.

Trimble has outperformed relative to its technology peers over the past year, and Wall Street analysts maintain a strongly optimistic view on the stock’s outlook.

Pool Corporation has struggled to keep up with the Dow Jones Industrial Average over the past year, and Wall Street analysts remain reasonably bullish about the stock’s prospects.

EQT Corporation has delivered stronger returns than the broader energy sector over the past year, fueling strong analyst confidence in the stock’s future performance.

Tar spot in corn has been around for several years, and researchers are still discovering things that might surprise producers.  Plant pathologist, researcher, and professor Dr. Damon Smith with the University of Wisconsin has more about tar spot next on today’s Managing for Profit. The post Some things about tar...

Pentair has notably outperformed the Nasdaq Composite over the past year, and analysts remain bullish about the stock’s prospects.

Walgreens has lagged behind the Nasdaq Composite over the past year, and analysts remain skeptical about the stock’s prospects.

Viatris has significantly underperformed the S&P 500 over the past year, and analysts remain cautious about the stock’s prospects.

Despite its underperformance compared to other REIT stocks over the past year, Host Hotels & Resorts has observed a notable surge in recent months and analysts remain optimistic about the stock’s prospects.

Universal Health Services has performed slightly better than the broader healthcare sector over the past year, and analysts remain optimistic about the stock’s prospects.

UDR has notably underperformed the Dow over the past year, yet analysts remain optimistic about the stock’s prospects.

Lamb Weston has lagged behind the Nasdaq Composite over the past year, though analysts maintain a moderately positive outlook on the stock’s future performance.

DaVita’s performance over the past year has fallen short of the broader S&P 500 Index, prompting a neutral outlook from analysts regarding its future prospects.

Incyte has underperformed relative to its biotech peers over the past year, though Wall Street analysts maintain a cautiously optimistic view on the stock’s outlook.